Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all ...
Europe's drugs regulator said on Friday it had launched a real-time review of CureVac's (5CV.DE), COVID-19 vaccine to speed ...
Investor's Business Daily on MSN
GSK Jumps On Hiked 2025 Outlook, But CEO Remains 'Very Cautious' About Vaccines
GSK stock rose early Wednesday on strong 2025 guidance on the back of its third-quarter sales and earnings beat.
Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of its COVID-19 vaccine in the U.S. as Americans struggled to access the shots.
MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.
Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...
LONDON (AP) — Drugmakers Sanofi and GlaxoSmithKline say they will seek regulatory approval for a new COVID-19 vaccine after human trials showed it provided a high level of protection against the ...
Medicago expects to begin Phase III study by end of 2020 First of GSK's COVID-19 vaccine tie-ups to start late-stage trials Early data showed vaccine produced virus-neutralizing antibodies Nov 12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback